Cargando…
Cannabis-based product use in a multiple sclerosis cohort
OBJECTIVE: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS) patients who attend the University of British Columbia Hospital (UBCH) MS clinic. METHODS: All patients attending the UBCH MS clinic from January to March 2018 were invited...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764052/ https://www.ncbi.nlm.nih.gov/pubmed/31598330 http://dx.doi.org/10.1177/2055217319869360 |
_version_ | 1783454296005672960 |
---|---|
author | Schabas, AJ Vukojevic, V Taylor, C Thu, Z Badyal, A Chan, JK Devonshire, V Traboulsee, A Sayao, AL Carruthers, R |
author_facet | Schabas, AJ Vukojevic, V Taylor, C Thu, Z Badyal, A Chan, JK Devonshire, V Traboulsee, A Sayao, AL Carruthers, R |
author_sort | Schabas, AJ |
collection | PubMed |
description | OBJECTIVE: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS) patients who attend the University of British Columbia Hospital (UBCH) MS clinic. METHODS: All patients attending the UBCH MS clinic from January to March 2018 were invited to participate in an anonymous survey that included: patient demographics (sex, age and employment status), self-reported MS-specific data (subtype, disease duration, previous and current disease modifying therapies, symptomatic medications) and CBP use (formulation, frequency, perceived benefits/side-effects). A second cohort of retrospective patient data (CBP use, sex, age, disease subtype and Expanded Disability Status Scale) was extracted from the UBCH MS clinic electronic medical record (EMR). RESULTS: Of 600 surveys distributed, 188 were returned with completed CBP usage. CBP use was daily for 19% (n = 37), weekly for 6% (n = 11), monthly for 4% (n = 7), rarely for 21% (n = 39) and 50% (n = 94) never used. Of the CBP users (daily, weekly and monthly), CBP use included: oral (n = 43/55), smoked/vaporized (n = 42/55), topical (n = 14/55) and mucosal (n = 5/55). EMR data was available for 561 MS patients where cannabis use/non-use was documented. CBP users represented 19% (107/561). CONCLUSIONS: CBP use is common based on volunteer reporting, with approximately one out of four patients who attend the UBCH MS clinic using CBPs. |
format | Online Article Text |
id | pubmed-6764052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67640522019-10-09 Cannabis-based product use in a multiple sclerosis cohort Schabas, AJ Vukojevic, V Taylor, C Thu, Z Badyal, A Chan, JK Devonshire, V Traboulsee, A Sayao, AL Carruthers, R Mult Scler J Exp Transl Clin Original Research Paper OBJECTIVE: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS) patients who attend the University of British Columbia Hospital (UBCH) MS clinic. METHODS: All patients attending the UBCH MS clinic from January to March 2018 were invited to participate in an anonymous survey that included: patient demographics (sex, age and employment status), self-reported MS-specific data (subtype, disease duration, previous and current disease modifying therapies, symptomatic medications) and CBP use (formulation, frequency, perceived benefits/side-effects). A second cohort of retrospective patient data (CBP use, sex, age, disease subtype and Expanded Disability Status Scale) was extracted from the UBCH MS clinic electronic medical record (EMR). RESULTS: Of 600 surveys distributed, 188 were returned with completed CBP usage. CBP use was daily for 19% (n = 37), weekly for 6% (n = 11), monthly for 4% (n = 7), rarely for 21% (n = 39) and 50% (n = 94) never used. Of the CBP users (daily, weekly and monthly), CBP use included: oral (n = 43/55), smoked/vaporized (n = 42/55), topical (n = 14/55) and mucosal (n = 5/55). EMR data was available for 561 MS patients where cannabis use/non-use was documented. CBP users represented 19% (107/561). CONCLUSIONS: CBP use is common based on volunteer reporting, with approximately one out of four patients who attend the UBCH MS clinic using CBPs. SAGE Publications 2019-09-25 /pmc/articles/PMC6764052/ /pubmed/31598330 http://dx.doi.org/10.1177/2055217319869360 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Schabas, AJ Vukojevic, V Taylor, C Thu, Z Badyal, A Chan, JK Devonshire, V Traboulsee, A Sayao, AL Carruthers, R Cannabis-based product use in a multiple sclerosis cohort |
title | Cannabis-based product use in a multiple sclerosis
cohort |
title_full | Cannabis-based product use in a multiple sclerosis
cohort |
title_fullStr | Cannabis-based product use in a multiple sclerosis
cohort |
title_full_unstemmed | Cannabis-based product use in a multiple sclerosis
cohort |
title_short | Cannabis-based product use in a multiple sclerosis
cohort |
title_sort | cannabis-based product use in a multiple sclerosis
cohort |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764052/ https://www.ncbi.nlm.nih.gov/pubmed/31598330 http://dx.doi.org/10.1177/2055217319869360 |
work_keys_str_mv | AT schabasaj cannabisbasedproductuseinamultiplesclerosiscohort AT vukojevicv cannabisbasedproductuseinamultiplesclerosiscohort AT taylorc cannabisbasedproductuseinamultiplesclerosiscohort AT thuz cannabisbasedproductuseinamultiplesclerosiscohort AT badyala cannabisbasedproductuseinamultiplesclerosiscohort AT chanjk cannabisbasedproductuseinamultiplesclerosiscohort AT devonshirev cannabisbasedproductuseinamultiplesclerosiscohort AT traboulseea cannabisbasedproductuseinamultiplesclerosiscohort AT sayaoal cannabisbasedproductuseinamultiplesclerosiscohort AT carruthersr cannabisbasedproductuseinamultiplesclerosiscohort |